Medication Use Policy

Remicade® (Infliximab)
Renflexis™ (infliximab-abda)
Inflectra® (infliximab-dyyb)
Ixifi™ (infliximab-qbtx)

FDA approval: Various
HCPCS: J1745/Q5104/Q5103
Benefit: Medical

Policy/Criteria:

Note: Requests must be supported by submission of chart notes and patient specific documentation.

A. Coverage of the requested drug is provided when FDA approved indications below are met with trial and failure of Inflectra, and where the member has had a documented negative TB test:
   a. Crohn’s disease when established by or in consultation with a specialist in gastroenterology:
      i. Active Crohn’s disease
         1. Treatment with an adequate course of systemic corticosteroid (e.g., prednisone, or prednisolone per day for 7 to 14 days) has been ineffective or is contraindicated
            OR
         2. The patient has been unable to taper off an adequate course of systemic corticosteroids without experiencing worsening of disease
            OR
         3. The patient is experiencing breakthrough disease (e.g., active disease flares) while stabilized for at least 2 months on immunomodulatory medication (such as azathioprine, mercaptopurine, cyclosporine, or methotrexate)
      ii. Fistulizing Crohn’s disease
   b. Pediatric Crohn’s disease
      i. Diagnosis established by or in consultation with a specialist in gastroenterology
      ii. The patient has had an inadequate response to conventional therapy
   c. Ulcerative colitis
      i. Diagnosis established by or in consultation with a specialist in gastroenterology
      ii. Treatment with an adequate course of systemic corticosteroid (e.g., prednisone, or prednisolone per day for 7 to 14 days) has been ineffective or is contraindicated
         OR
iii. The patient has been unable to taper off an adequate course of systemic corticosteroids without experiencing worsening of disease  

OR  

iv. The patient is experiencing breakthrough disease (e.g., active disease flares) while stabilized for at least 2 months on immunomodulatory medication (such as azathioprine, mercaptopurine, cyclosporine, or methotrexate)  

d. Pediatric ulcerative colitis  
   i. Diagnosis established by or in consultation with a specialist in gastroenterology  
   ii. The patient has had an inadequate response to conventional therapy  

e. Rheumatoid arthritis  
   i. Diagnosis established by or in consultation with a specialist in rheumatology  
   ii. There is clinical documentation that an oral DMARD (such as methotrexate) was not effective after at least a 6 to 12-week treatment course  
   iii. Remicade, Inflectra, Ixifi and Renflexis are administered with methotrexate  

f. Psoriatic arthritis  
   i. Diagnosis established by or in consultation with a specialist in dermatology or rheumatology  

g. Plaque psoriasis  
   i. Diagnosis established by or in consultation with a specialist in dermatology or rheumatology  
   ii. Diagnosis of chronic severe (i.e., extensive and/or disabling) plaque psoriasis  
   iii. Clinical documentation supports involvement of at least 10% of the body surface area or there is significant functional disability  
   iv. Treatment with phototherapy (for example, UVB) or photochemotherapy was not effective, not tolerated, or is contraindicated  
   v. Treatment with at least one oral systemic agent for psoriasis was ineffective or not tolerated, unless all are contraindicated. Examples of systemic agents include, but are not limited to, cyclosporine, methotrexate, and acitretin  

h. Ankylosing spondylitis  
   i. Diagnosis established by or in consultation with a specialist in rheumatology  

B. Quantity Limitations, Authorization Period, and Renewal Criteria  

a. Initial: 5 mg/kg at 0, 2, and 6 weeks except 3 mg/kg for rheumatoid arthritis  

b. Continued: 3 mg/kg every 8 weeks for rheumatoid arthritis and 5 mg/kg every 8 weeks except every 6 weeks for ankylosing spondylitis.  

c. Approval duration: 1 year  

d. Renewal: 1 year  

e. Authorization may be reviewed at least annually to confirm that current medical necessity criteria are met and that the medication is effective:  
   i. Crohn’s disease:  
      1. Active Crohn’s disease:  
         a. Reducing signs and symptoms, inducing, and maintaining clinical remission  
      2. Fistulizing Crohn’s disease  
         a. Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease  
   ii. Pediatric Crohn’s disease:  
      1. Reducing signs and symptoms, inducing, and maintaining clinical remission  
   iii. Ulcerative colitis:  
      1. Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients  

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.
iv. Pediatric ulcerative colitis:
   1. Reducing signs and symptoms, inducing, and maintaining clinical remission

v. Rheumatoid arthritis:
   1. Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function

vi. Psoriatic arthritis:
   1. Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function

vii. Plaque psoriasis:
   1. Documentation of beneficial clinical response defined as achieving a PASI 75 response or equivalent response such as greater than 50% reduction in Body Surface Area (BSA) covered by psoriasis compared to baseline

viii. Ankylosing spondylitis:
   1. Reducing signs and symptoms in patients with active disease

C. Remicade, Inflectra, Ixifi and Renflexis are considered investigational when used for all other conditions, including but not limited to:
   a. Behçet syndrome uveitis
   b. Celiac sprue
   c. Chronic obstructive pulmonary disease (stable)
   d. Giant cell arteritis
   e. Graft versus host disease (adults)
   f. Graft versus host disease (children/adolescents)
   g. Hidradenitis suppurativa (adults)
   h. Juvenile idiopathic arthritis
   i. Pustular psoriasis
   j. Pyoderma gangrenosum
   k. Sarcoidosis
   l. Uveitis
   m. Wegener granulomatosis

***Note: Coverage may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at http://www.cms.hhs.gov/. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia

Therapeutic considerations:

A. FDA approved indication / Diagnosis:
   Remicade, Inflectra, Ixifi and Renflexis are a tumor necrosis factor (TNF) blocker that is indicated for Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.

*Please refer to most recent prescribing information.

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.
B. Background Information

- Crohn’s disease (CD) is a chronic inflammatory disorder that is characterized by focal, asymmetric, transmural, and granulomatous inflammation which primarily affects the gastrointestinal tract.
  - Therapeutic recommendations are individualized and depend on disease location, severity, and complications present. Treatment options for CD include: glucocorticoids (conventional steroids and budesonide), immunosuppressants (azathioprine, mercaptopurine, methotrexate), 5-aminosalicylates (5-ASA), and biologic agents [infliximab (Remicade®), adalimumab (Humira®), natalizumab (Tysabri®), certolizumab (Cimzia®), and vedolizumab (Entyvio®)].
- Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that causes long-lasting inflammation and ulcers (sores) in the digestive tract.
  - Treatment options for UC include: glucocorticoids (conventional steroids and budesonide), immunosuppressants (azathioprine, mercaptopurine, methotrexate), 5-aminosalicylates (5-ASA), and biologic agents (Remicade, Humira, Tysabri, Cimzia, and Entyvio).
- Rheumatoid arthritis (RA) is an autoimmune disease that most commonly affects the wrists, fingers, knees, feet, and ankle joints symmetrically.
  - Treatment options for RA include: glucocorticoids (most often used for short-term management of flares), disease-modifying anti-rheumatic drugs (DMARDs): hydroxychloroquine, leflunomide, methotrexate, minocycline, and sulfasalazine; and biologic agents [non-TNF: abatacept (Orencia®), rituximab (Rituxan®), tocilizumab (Actemra®); anti-TNF: Humira, entanercept (Enbrel®), Remicade, Cimzia, and golimumab (Simponi®)].
- Psoriatic Arthritis (PsA) is a chronic inflammatory disease often associated with psoriasis. Psoriasis is an autoimmune disease affecting the skin, resulting in scaly red and white patches.
  - Treatment options include NSAIDs, DMARDs, and anti-TNF biologic agents. If PsA does not respond to the initial treatment [NSAIDs, DMARDs (sulfasalazine, methotrexate, cyclosporine, and leflunomide)] as monotherapy, combination therapy may be used. Hydroxychloroquine should be avoided due to exacerbation of psoriasis. Anti-TNF agents may be utilized when initial treatment has been ineffective. Anti-TNF agents approved for PsA include: Humira, Enbrel, Remicade, Cimzia, and Simponi.
- Psoriasis is a complex autoimmune inflammatory disease that occurs in genetically susceptible individuals and presents with the development of inflammatory plaques on the skin.
  - Treatment options include: phototherapy or photochemotherapy, DMARDs: cyclosporine, methotrexate, and acitretin. Anti-TNF agents may be utilized when initial treatment has been ineffective. Anti-TNF agents approved for plaque psoriasis include: Humira, Enbrel, and Remicade.
- Ankylosing Spondylitis (AS) belongs to a group of chronic rheumatic diseases affecting the bones and joints connecting the spine and pelvis known as spondyloarthritis.
  - Treatment options include NSAIDs, corticosteroids, DMARDs, and anti-TNF biologic agents. Anti-inflammatory agents such as NSAIDs may be used to reduce swelling; however, they do not affect disease progression. DMARDs (sulfasalazine and methotrexate) have not been proven effective for the treatment of axial disease. Anti-TNF agents (Enbrel, Humira, Remicade, Cimzia or Simponi) target the pathophysiologic mechanism of AS and have been shown to be beneficial and effective.

C. Efficacy:

*Please refer to most recent prescribing information.

D. Medication Safety Considerations

Boxed Warning: Yes
E. Dosing and administration

a. Dosing:
   i. Crohn’s disease
      1. Initial: 5 mg/kg at 0, 2, and 6 weeks
      2. Maintenance: 5 mg/kg every 8 weeks
   ii. Ulcerative colitis
      1. Initial: 5 mg/kg at 0, 2, and 6 weeks
      2. Maintenance: 5 mg/kg every 8 weeks
   iii. Rheumatoid arthritis in conjunction with methotrexate
      1. Initial: 3 mg/kg at 0, 2, and 6 weeks
      2. Maintenance: 3 mg/kg every 8 weeks
   iv. Psoriatic arthritis and plaque psoriasis
      1. Initial: 5 mg/kg at 0, 2, and 6 weeks
      2. Maintenance: 5 mg/kg every 8 weeks
   v. Ankylosing spondylitis
      1. Initial: 5 mg/kg at 0, 2, and 6 weeks
      2. Maintenance: 5 mg/kg every 6 weeks

*Please refer to most recent prescribing information.

F. How supplied

a. Solution Reconstituted, intravenous containing 100 mg of infliximab/infliximab-abda/infliximab-dyyb/infliximab-qbtx

References:

4. Ixifi™ [prescribing information]. Ireland: Pfizer Ireland Pharmaceuticals; December 2017.
11. Goekoop-Ruiterman, YP, de Vries-Bouwstra, JK, Allaart, CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis and


Policy History

<table>
<thead>
<tr>
<th>#</th>
<th>Date</th>
<th>Change Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Effective Date: 05/05/2016</td>
<td>New policy</td>
</tr>
<tr>
<td>1.1</td>
<td>Effective Date: 05/04/2017</td>
<td>Annual Review and template update</td>
</tr>
<tr>
<td>1.2</td>
<td>Effective Date: 2/8/2018</td>
<td>Added additional drugs including biosimilars</td>
</tr>
<tr>
<td>1.3</td>
<td>Effective Date: 3/9/2018</td>
<td>Added additional drugs and step therapy criteria</td>
</tr>
<tr>
<td>1.4</td>
<td>Effective Date: 9/7/2018</td>
<td>The Treatments for RA Policy is being retired; adding RA criteria back in this document</td>
</tr>
</tbody>
</table>

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.
* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or http://dailymed.nlm.nih.gov/dailymed/index.cfm